VEA
Virtus ETF Advisers Portfolio holdings
AUM
$75.7M
1-Year Return
23.01%
This Quarter Return
-1.04%
1 Year Return
+23.01%
3 Year Return
+79.79%
5 Year Return
+153.94%
10 Year Return
–
AUM
$165M
AUM Growth
-$4.08M
(-2.4%)
Cap. Flow
+$1.01M
Cap. Flow
% of AUM
0.61%
Top 10 Holdings %
Top 10 Hldgs %
6.09%
Holding
488
New
53
Increased
73
Reduced
307
Closed
54
Top Buys
| 1 |
Halliburton
HAL
|
$819K |
| 2 |
Alphabet (Google) Class A
GOOGL
|
$814K |
| 3 |
Steel Dynamics
STLD
|
$798K |
| 4 |
Caterpillar
CAT
|
$792K |
| 5 |
Booking.com
BKNG
|
$789K |
Top Sells
| 1 |
Netflix
NFLX
|
$1.05M |
| 2 |
Vulcan Materials
VMC
|
$1.01M |
| 3 |
CoStar Group
CSGP
|
$998K |
| 4 |
Eli Lilly
LLY
|
$967K |
| 5 |
Ingersoll Rand
IR
|
$913K |
Sector Composition
| 1 | Healthcare | 18.63% |
| 2 | Financials | 17.26% |
| 3 | Technology | 14.89% |
| 4 | Energy | 9.42% |
| 5 | Consumer Discretionary | 8.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
326
Revolution Medicines
RVMD
$7.57B
| $108K | 0.07% |
3,916
-390
| -9% | -$10.8K |
|
|
SAGE
327
DELISTED
Sage Therapeutics
SAGE
| $108K | 0.07% |
5,240
-680
| -11% | -$14K |
|
328
IDEAYA Biosciences
IDYA
$2.38B
| $107K | 0.07% |
3,977
-401
| -9% | -$10.8K |
|
329
Nuvalent
NUVL
$5.83B
| $106K | 0.06% |
2,296
-228
| -9% | -$10.5K |
|
330
Biohaven
BHVN
$1.68B
| $106K | 0.06% |
4,057
-403
| -9% | -$10.5K |
|
331
Caribou Biosciences
CRBU
$174M
| $102K | 0.06% |
21,358
-2,128
| -9% | -$10.2K |
|
332
BlackRock 2037 Municipal Target Term Trust
BMN
$151M
| $102K | 0.06% |
+4,479
| New | +$102K |
|
333
PMV Pharmaceuticals
PMVP
$77.4M
| $102K | 0.06% |
16,534
-1,650
| -9% | -$10.1K |
|
334
Ardelyx
ARDX
$1.57B
| $100K | 0.06% |
24,595
-2,454
| -9% | -$10K |
|
335
Ventyx Biosciences
VTYX
$180M
| $98.1K | 0.06% |
2,825
-278
| -9% | -$9.66K |
|
|
XIFR
336
XPLR Infrastructure, LP
XIFR
$976M
| $97.3K | 0.06% |
3,275
-431
| -12% | -$12.8K |
|
337
Vaxcyte
PCVX
$4.29B
| $96K | 0.06% |
1,883
-192
| -9% | -$9.79K |
|
338
Immatics
IMTX
$761M
| $95.7K | 0.06% |
8,263
-825
| -9% | -$9.55K |
|
339
AnaptysBio
ANAB
$613M
| $95.6K | 0.06% |
5,323
-536
| -9% | -$9.63K |
|
340
Summit Therapeutics
SMMT
$19.3B
| $94.8K | 0.06% |
50,714
-5,049
| -9% | -$9.44K |
|
341
Disc Medicine
IRON
$2.11B
| $94.6K | 0.06% |
2,014
-205
| -9% | -$9.63K |
|
342
Arcellx
ACLX
$4.03B
| $93.5K | 0.06% |
2,605
-261
| -9% | -$9.37K |
|
|
CMPS
343
Compass Pathways
CMPS
$493M
| $92.9K | 0.06% |
12,549
-1,250
| -9% | -$9.25K |
|
344
Novavax
NVAX
$1.28B
| $92.8K | 0.06% |
12,813
-1,272
| -9% | -$9.21K |
|
345
Arcturus Therapeutics
ARCT
$485M
| $91.5K | 0.06% |
3,582
-354
| -9% | -$9.05K |
|
346
Akero Therapeutics
AKRO
$3.58B
| $90.8K | 0.06% |
1,795
-176
| -9% | -$8.9K |
|
347
Arcus Biosciences
RCUS
$1.3B
| $90.5K | 0.06% |
5,042
-506
| -9% | -$9.08K |
|
348
Day One Biopharmaceuticals
DAWN
$773M
| $90.1K | 0.05% |
7,339
-734
| -9% | -$9.01K |
|
349
Rocket Pharmaceuticals
RCKT
$354M
| $89.3K | 0.05% |
4,356
-436
| -9% | -$8.93K |
|
350
Krystal Biotech
KRYS
$4.35B
| $88.9K | 0.05% |
766
-74
| -9% | -$8.58K |
|